Analyzing Responses to 177LuPSMA-617 in Patients With Metastatic CRPC
Jeremie Calais, MD, discusses the results from a preliminary analysis of a phase II trial investigating 177 lutetium prostate-specific membrane antigen-617 in patients with metastatic castration-resistant prostate cancer.
Jeremie Calais, MD, assistant clinical professor, Department of Nuclear Medicine, Ahmanson Translational Imaging Division, discusses the results from a preliminary analysis ofa phase II trial investigating 177 lutetium prostate-specific membrane antigen-617(177LuPSMA-617) in patients with metastatic castration-resistant prostate cancer.
Prostate-specific antigen (PSA) levels, which was the primary endpoint of the study, declined by at least 50% after 2 cycles of therapy. This seems early, Calais says, but the retrospective analysis data appeared promising.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
